Circulating sex hormones and terminal duct lobular unit involution of the normal breast

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2765-2773

  Khodr, Zeina G ^a   Sherman, Mark E ^a   Pfeiffer, Ruth M ^a   Gierach, Gretchen L ^a   Brinton, Louise A ^a   Falk, Roni T ^a   Patel, Deesha A ^a   Linville, Laura M ^b   Papathomas, Daphne ^a   Clare, Susan E ^c   Visscher, Daniel W ^d   Mies, Carolyn ^e   Hewitt, Stephen M ^a   Storniolo, Anna Maria V ^f   Rosebrock, Adrian ^g   Caban, Jesus J ^h   Figueroa, Jonine D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Baltimore County   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROGESTERONE; PROLACTIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; BREAST DUCT; CANCER PATIENT; CANCER RISK; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; INVOLUTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MENOPAUSE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREDICTIVE VALUE; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; REPRODUCIBILITY; TERMINAL DUCT LOBULAR UNIT INVOLUTION; TESTOSTERONE BLOOD LEVEL; TISSUE SECTION; TREND STUDY; ADOLESCENT; ANATOMY AND HISTOLOGY; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 84919339726     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0667     Document Type: Article

References (54)

1. Wellings SR, Jensen HM, Marcum RG An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975; 55: 231-73.
2. Lanigan F, O'Connor D, Martin F, Gallagher WM Molecular links between mammary gland development and breast cancer. Cell Mol Life Sci 2007; 64: 3159-84.
3. Pike MC, Krailo MD, Henderson B.E., Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983; 303: 767-70.
4. Henson DE, Tarone RE On the possible role of involution in the natural history of breast cancer. Cancer 1993; 71: 2154-6.
5. Cowan DF, Herbet TA Involution of the breast in women aged 50 to 104 years: a histopathological study of 102 cases. Surg Pathol 1989; 2: 323-33.
6. Hutson SW, Cowen PN, Bird CC Morphometric studies of age related changes in normal human breast and their significance for evolution of mammary cancer. J Clin Pathol 1985; 38: 281-7.
7. Tavassoli F. Normal development and anomalies. In: Medina MG, editor. Pathology of the Breast. Hong Kong: McGraw-Hill Professional; 1999.p. 1-25.
8. Hovey RC, Trott JF Morphogenesis of mammary gland development. Adv Exp Med Biol 2004; 554: 219-28.
9. McKian KP, Reynolds CA, Visscher D.W., Nassar A., Radisky DC, Vierkant RA, et al. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 2009; 27: 5893-8.
10. Milanese TR, Hartmann LC, Sellers T.A., Frost MH, Vierkant RA, Maloney SD, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006; 98: 1600-7.
11. Baer HJ, Collins LC, Connolly J.L., Colditz GA, Schnitt SJ, Tamimi RM. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer 2009; 115: 1404-11.
12. Ghosh K, Hartmann LC, Reynolds C, Visscher D.W., Brandt KR, Vierkant RA, et al. Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol 2010; 28: 2207-12.
13. Ginsburg OM, Martin LJ, Boyd NF Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 2008; 99: 1369-74.
14. Henson DE, Tarone RE Involution and the etiology of breast cancer. Cancer 1994; 74: 424-9.
15. Figueroa JD, Pfeiffer RM, Patel D.A., Linville L., Brinton LA, Gierach GL, et al. Terminal duct lobular unit involution of the normal breast: Implications for breast cancer etiology. J Natl Cancer Inst 2014; 106. pii: dju286.
16. Butler L, Santoro N. The reproductive endocrinology of the meno-pausal transition. Steroids 2011; 76: 627-35.
17. Eliassen AH, Tworoger SS, Hankinson SE Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 2007; 120: 1536-41.
18. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 3-15.
19. Key TJ, Appleby PN, Reeves G.K., Roddam AW, Helzlsouer KJ, Alberg AJ, et al Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011; 105: 709-22.
20. Key T, Appleby P, Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-16.
21. Key TJ, Appleby PN, Reeves G.K., Travis RC, Alberg AJ, Barricarte A, et al Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013; 14: 1009-19.
22. Tworoger SS, Eliassen AH, Zhang X, Qian J., Sluss PM, Rosner BA, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013; 73: 4810-9.
23. Sherman ME, Figueroa JD, Henry J.E., Clare SE, Rufenbarger C, Storniolo AM. The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the "molecular histology" of the breast. Cancer Prev Res 2012; 5: 528-35.
24. Susan G. Komen Tissue Bank at the IU Simon Cancer Center; c2011-2014; 2014 [updated 2014 Aug 11; cited 2014 Aug 11]. Available from: http://komentissuebank.iu.edu.
25. Rosebrock A, Caban JJ, Figueroa J, Gierach G., Linville L, Hewitt S, et al Quantitative analysis of TDLUs using adaptive morphological shape techniques. SPIE Proceedings; 2013. p. 86760N-N-6.
26. Vermeulen A, Verdonck L, Kaufman JM A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
27. Hall JE. Neuroendocrine control of the menstrual cycle. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia, PA: Saunders Elsevier; 2009. p. 139-54.
28. Lobo RA. Menopause and aging. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe's reproductive endocrinology: physiology, pathophys-iology, and clinical management. Philadelphia, PA: Saunders Elsevier; 2009. p. 325-55.
29. Schreiber CA, Barnhart K. Contraception. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia, PA: Saun-ders Elsevier; 2009. p. 873-92.
30. Long JS. Count outcomes: regression models for counts. In: Bentler P, Muthen B, Rigby D, Read D, Leamer E, Ylvisaker D, editors. Advanced quantitative techniques in the social sciences. Thousand Oaks, CA: SAGE Publications, Inc.; 1997. p. 217-50.
31. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten A.A., et al. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988; 24: 1225-31.
32. Faupel-Badger J.M., Sherman ME, Garcia-Closas M, Gaudet M.M., Falk RT, Andaya A, et al. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 2010; 103: 1097-102.
33. Dickson RB, Stancel GM Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000:135-45.
34. Hankinson SE, Eliassen AH Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 2007; 106: 24-30.
35. Zhang X, Tworoger SS, Eliassen A.H., Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013; 137: 883-92.
36. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009; 11:212.
37. Kaaks R, Tikk K, Sookthai D., Schock H, Johnson T, Tjonneland A., et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort. Int J Cancer. 2014; 134: 1947-57.
38. Farhat GN, Cummings SR, Chlebowski R.T., Parimi N., Cauley JA, Rohan TE, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011; 103: 562-70.
39. Manjer J, Johansson R, Berglund G., Janzon L, Kaaks R, Agren A., et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003; 14: 599-607.
40. Zeleniuch-Jacquotte A., Afanasyeva Y, Kaaks R., Rinaldi S, Scarmo S, Liu M., et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res 2012; 14:R32.
41. Dorgan JF, Stanczyk FZ, Kahle L.L., Brinton LA. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2010; 12:R98.
42. Micheli A, Secreto G, Meneghini E., Krogh V, Muti P, Venturelli E., et al. Re: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2007; 99: 408-9.
43. Chlebowski RT, Manson JE, Anderson G.L., Cauley JA, Aragaki AK, Stefanick ML, et al Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013; 105: 526-35.
44. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-11.
45. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012; 15 (SUPPL. 1):18-25.
46. Shapiro S, deVilliers TJ, Pines A, Sturdee D.W., Archer DF, Baber RJ, et al. Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study. J Natl Cancer Inst 2014; 106:djt372.
47. Kuhl H, Schneider HP Progesterone-promoter or inhibitor of breast cancer. Climacteric. 2013; 16 (SUPPL. 1):54-68.
48. Barbieri R. The breast. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia, PA: Saunders Elsevier; 2009. p. 235-48.
49. Hankinson SE, Willett WC, Michaud D.S., Manson JE, Colditz GA, Longcope C, et al Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 629-34.
50. Tworoger SS, Eliassen AH, Rosner B, Sluss P., Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-9.
51. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007; 25: 1482-8.
52. Tikk K, Sookthai D, Johnson T., Rinaldi S, Romieu I, Tjonneland A., et al. Circulating prolactin and breast cancer risk among pre- and postmen-opausal women in the EPIC cohort. Ann Oncol 2014; 25: 1422-8.
53. Tworoger SS, Sluss P, Hankinson SE Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006; 66: 2476-82.
54. Degnim AC, Visscher DW, Hoskin T.L., Frost MH, Vierkant RA, Vachon CM, et al Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat 2012; 133: 169-77.